A review of the latest leadership moves in the pharma industry.
Illumina Inc. on Friday said it had expanded its board, adding two C-suite executives a week after shareholders voted to replace the gene sequencing company’s chairman with activist investor Carl Icahn’s nominee.
Novartis’ breast cancer drug Kisqali cut the risk of recurrence by a little more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and challenging strong rival Eli Lilly.
A federal appeals court, in a decision unsealed Wednesday, upheld the dismissal of a whistleblower lawsuit against Johnson & Johnson as a sanction for the plaintiffs’ misuse of confidential records they obtained through related litigation.
Gambia has hired a U.S. law firm to explore legal action after a government-backed investigation found that contaminated medicines from India were “very likely” to have caused the deaths of children last year, the justice minister told Reuters.
U.S. President Joe Biden plans to select former North Carolina health secretary Mandy Cohen to lead the Centers for Disease Control and Prevention, the Washington Post reported on Thursday, citing three people with direct knowledge of the situation.
The U.S. Supreme Court on Thursday gave a boost to whistleblowers in their bid to revive lawsuits accusing pharmacy operators of knowingly overbilling government health insurance programs for prescription drugs at taxpayers’ expense.
The Medicare health plan will cover new Alzheimer’s drugs after full U.S. approval for patients who participate in a health agency database, a move that expands on conditional coverage terms but companies have said that would limit use.
British drugmaker AstraZeneca (AZN.L) said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis.
Coherus BioSciences Inc. said on Thursday it plans to launch a biosimilar of AbbVie Inc’s (ABBV.N) Humira in July at a list price of $995 per carton, representing a discount of about 85% from the blockbuster arthritis drug.